MARCH8 inhibits human immunodeficiency virus type 1(HIV-1) infection by binding to and downregulating HIV-1 envelope glycoprotein (Env), whereas its tyrosine motif mutation (222AxxL225) cannot downregulate HIV-1 Env [5, 6]. Here, MARCHF8 is linked to HIV-1 infection.